These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 12942575)

  • 21. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
    López-Bonet E; Alonso-Ruano M; Barraza G; Vazquez-Martin A; Bernadó L; Menendez JA
    Oncol Rep; 2008 Dec; 20(6):1369-74. PubMed ID: 19020716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metaplastic breast carcinoma: pathology and clinical outcome.
    Bellino R; Arisio R; D'Addato F; Attini R; Durando A; Danese S; Bertone E; Grio R; Massobrio M
    Anticancer Res; 2003; 23(1B):669-73. PubMed ID: 12680165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infiltrating micropapillary carcinoma of the breast.
    Middleton LP; Tressera F; Sobel ME; Bryant BR; Alburquerque A; Grases P; Merino MJ
    Mod Pathol; 1999 May; 12(5):499-504. PubMed ID: 10349988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer in young women: clinicopathologic correlation.
    Bertheau P; Steinberg SM; Cowan K; Merino MJ
    Semin Diagn Pathol; 1999 Aug; 16(3):248-56. PubMed ID: 10490201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
    Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
    Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology and behavior of small breast carcinomas.
    Meyer JS; Fahrner M; Daniel FC
    Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study.
    Hartley MC; McKinley BP; Rogers EA; Kalbaugh CA; Messich HS; Blackhurst DW; Lokey JS; Trocha SD
    Am Surg; 2006 Dec; 72(12):1189-94; discussion 1194-5. PubMed ID: 17216817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases.
    Moran CA; Suster S; Koss MN
    Cancer; 1997 Aug; 80(4):699-707. PubMed ID: 9264353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An analysis of prognostic features in infiltrating lobular carcinoma of the breast.
    Frost AR; Terahata S; Yeh IT; Siegel RS; Overmoyer B; Silverberg SG
    Mod Pathol; 1995 Oct; 8(8):830-6. PubMed ID: 8552571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.